MEP20408A - Pharmaceutical dronedarone composition for parenteral administration - Google Patents

Pharmaceutical dronedarone composition for parenteral administration

Info

Publication number
MEP20408A
MEP20408A MEP-204/08A MEP20408A MEP20408A ME P20408 A MEP20408 A ME P20408A ME P20408 A MEP20408 A ME P20408A ME P20408 A MEP20408 A ME P20408A
Authority
ME
Montenegro
Prior art keywords
pharmaceutical
parenteral administration
dronedarone
composition
dronedarone composition
Prior art date
Application number
MEP-204/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Sanofi-Synthelabo
Frederique Bourriague-Seve
Thierry Breul
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of MEP20408A publication Critical patent/MEP20408A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MEP-204/08A 2000-12-11 2001-12-10 Pharmaceutical dronedarone composition for parenteral administration MEP20408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0016071A FR2817750B1 (fr) 2000-12-11 2000-12-11 Composition pharmaceutique de dronedarone pour administration parenterale
PCT/FR2001/003903 WO2002047660A1 (fr) 2000-12-11 2001-12-10 Composition pharmaceutique de dronedarone pour administration parenterale

Publications (1)

Publication Number Publication Date
MEP20408A true MEP20408A (en) 2010-06-10

Family

ID=8857483

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-204/08A MEP20408A (en) 2000-12-11 2001-12-10 Pharmaceutical dronedarone composition for parenteral administration
MEP-2008-204A ME00083B (me) 2000-12-11 2001-12-10 Farmaceutski oblik dronedarona za parenteralnu upotrebu

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-204A ME00083B (me) 2000-12-11 2001-12-10 Farmaceutski oblik dronedarona za parenteralnu upotrebu

Country Status (30)

Country Link
US (1) US6939865B2 (cs)
EP (1) EP1343473B1 (cs)
JP (1) JP4399161B2 (cs)
KR (1) KR100849758B1 (cs)
CN (1) CN1235566C (cs)
AR (1) AR031649A1 (cs)
AT (1) ATE348599T1 (cs)
AU (2) AU2002217229B2 (cs)
BG (1) BG66187B1 (cs)
BR (1) BR0116060B1 (cs)
CA (1) CA2427375C (cs)
CZ (1) CZ297788B6 (cs)
DE (1) DE60125411T2 (cs)
EA (1) EA005314B1 (cs)
FR (1) FR2817750B1 (cs)
HU (1) HU229372B1 (cs)
IL (2) IL155428A0 (cs)
IS (1) IS2349B (cs)
MA (1) MA26969A1 (cs)
ME (2) MEP20408A (cs)
MX (1) MXPA03005221A (cs)
NO (1) NO332294B1 (cs)
NZ (1) NZ525661A (cs)
OA (1) OA12416A (cs)
PL (1) PL199846B1 (cs)
RS (1) RS50348B (cs)
SK (1) SK287115B6 (cs)
TW (1) TWI246926B (cs)
WO (1) WO2002047660A1 (cs)
ZA (1) ZA200303406B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984028A2 (en) * 2006-02-14 2008-10-29 Wyeth a Corporation of the State of Delaware Aqueous pharmaceutical formulations of er selective ligands
GB0719180D0 (en) * 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
EP2684564A1 (en) 2008-04-17 2014-01-15 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
KR20120094557A (ko) * 2011-02-01 2012-08-27 동아제약주식회사 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제
CN102908307A (zh) * 2011-08-03 2013-02-06 天津市嵩锐医药科技有限公司 供注射用盐酸决奈达隆药物组合物及其制备方法
MX2015000532A (es) * 2012-07-12 2015-05-15 Sanofi Sa Composicion anti-tumoral que comprende el compuesto 1- (6- { [6- (4-fluorofenil) [1,2,4] triazolo [4,3-b] piridazin-3-il] sulfanil} -1,3-benzotiazol-2-il) -3- (2-morfolin-4-iletil) urea.
TWI901795B (zh) * 2020-10-20 2025-10-21 大陸商上海雲晟研新生物科技有限公司 鹽酸決奈達隆藥物組合物、其製備方法及應用
CN115702878B (zh) * 2021-08-16 2024-05-10 上海云晟研新生物科技有限公司 盐酸决奈达隆注射组合物、其制备方法及应用
WO2024120458A1 (zh) * 2022-12-07 2024-06-13 荣昌生物制药(烟台)股份有限公司 TACI-Fc融合蛋白液体药物制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2004327321A (ja) * 2003-04-25 2004-11-18 Jst Mfg Co Ltd コネクタ

Also Published As

Publication number Publication date
ATE348599T1 (de) 2007-01-15
BG66187B1 (bg) 2011-12-30
FR2817750B1 (fr) 2003-02-21
PL199846B1 (pl) 2008-11-28
US20040044070A1 (en) 2004-03-04
AU1722902A (en) 2002-06-24
OA12416A (fr) 2006-04-18
EP1343473A1 (fr) 2003-09-17
IL155428A0 (en) 2003-11-23
MXPA03005221A (es) 2004-03-26
SK7262003A3 (en) 2004-02-03
BG107748A (bg) 2004-03-31
NO20031958L (no) 2003-06-11
BR0116060A (pt) 2004-03-02
SK287115B6 (sk) 2009-12-07
BR0116060B1 (pt) 2013-12-31
JP4399161B2 (ja) 2010-01-13
HK1055906A1 (en) 2004-01-30
IS6801A (is) 2003-04-30
TWI246926B (en) 2006-01-11
NZ525661A (en) 2004-11-26
WO2002047660A1 (fr) 2002-06-20
PL362788A1 (en) 2004-11-02
FR2817750A1 (fr) 2002-06-14
ME00083B (me) 2010-10-10
US6939865B2 (en) 2005-09-06
HUP0500842A2 (hu) 2005-12-28
KR20030060985A (ko) 2003-07-16
HU229372B1 (en) 2013-11-28
AR031649A1 (es) 2003-09-24
CA2427375C (fr) 2011-02-01
YU46503A (sh) 2006-08-17
IL155428A (en) 2007-10-31
ZA200303406B (en) 2004-05-03
IS2349B (is) 2008-04-15
JP2004528277A (ja) 2004-09-16
CZ297788B6 (cs) 2007-03-28
DE60125411T2 (de) 2007-10-11
MA26969A1 (fr) 2004-12-20
AU2002217229B2 (en) 2006-05-18
EP1343473B1 (fr) 2006-12-20
KR100849758B1 (ko) 2008-07-31
NO20031958D0 (no) 2003-04-29
CZ20031612A3 (cs) 2003-09-17
DE60125411D1 (de) 2007-02-01
NO332294B1 (no) 2012-08-20
CN1479610A (zh) 2004-03-03
EA005314B1 (ru) 2004-12-30
EA200300406A1 (ru) 2003-10-30
CA2427375A1 (fr) 2002-06-20
CN1235566C (zh) 2006-01-11
RS50348B (sr) 2009-11-10

Similar Documents

Publication Publication Date Title
HRP20020880B1 (en) New pharmaceutical composition
MEP33708A (hr) Farmaceutske smješe koje obuhvataju inhibitor hmg coa reduktaze
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
MEP39108A (en) Pharmaceutical composition
EE200200486A (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, uued derivaadid ja nende valmistamismeetodid
EP1246622A4 (en) NEW SUBSTITUTED DOSE FORMS OF BENZIMIDAZOLENES AND METHOD FOR THE USE THEREOF
HRP20020198B1 (hr) Formulacija moksifloksacina i kuhinjske soli
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DK1766003T3 (da) Thrombinpræparater
FR2789079B3 (fr) Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
MY122124A (en) Solid pharmaceutical composition containing benzofurane derivatives
HRP20010243B1 (hr) Pripravci koji sadrže difosfonske kiseline
BG102857A (en) Antimycotic substance-containing and acetate buffer-containing compositions
NO976125D0 (no) Farmasöytisk amiodaronblanding for parenteral levering
YU46503A (sh) Farmaceutski oblik dronedarona za parenteralnu upotrebu
ATE198834T1 (de) Konjugate bestehend aus polysaccharid und protein
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
MXPA01011842A (es) Composiciones farmaceuticas para la administracion oral de floroglucinol y preparacion de las mismas.
SE0001916D0 (sv) Novel formulation
MXPA03004111A (es) Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion.
CL2011000439A1 (es) Formulacion farmaceutica que consiste esencialmente de 50 mg/ml de clorhidrato de canfosfamida en 100 mm de un amortiguador acuoso de citrato de sodio a ph 4,6; formulacion liofilizada que la comprende; y metodo de preparacion de la formulacion farmaceutica.